

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
8 February 2001 (08.02.2001)

PCT

(10) International Publication Number
WO 01/09097 A1

(51) International Patent Classification⁷: C07D 213/40,
A61K 31/4427, 31/4409, A61P 25/00

(21) International Application Number: PCT/US00/18578

(22) International Filing Date: 6 July 2000 (06.07.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/146,588 30 July 1999 (30.07.1999) US

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): VERTEX PHARMACEUTICALS INCORPORATED [US/US]; 130 Waverly Street, Cambridge, MA 02139-4242 (US).

Published:

- With international search report.
- Before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments.

(72) Inventors; and


(75) Inventors/Applicants (*for US only*): MULLICAN, Michael [US/US]; 110 Parker Road, Needham, MA 02194 (US). LAUFFER, David [US/US]; 254 Taylor Road, Stow, MA 01775 (US).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(74) Agents: MARKS, Andrew et al.; Vertex Pharmaceuticals Inc., 130 Waverly Street, Cambridge, MA 02139-4242 (US).

WO 01/09097 A1

(54) Title: CYCLIC AMINE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISEASES



(57) Abstract: The present invention relates to cyclic amine derivatives of general formula (I) for treating or preventing neuronal damage associated with neurological diseases. The invention also provides compositions comprising the compounds of the present invention and methods of utilizing those compositions for treating or preventing neuronal damage.

CYCLIC AMINE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISEASES

TECHNICAL FIELD OF THE INVENTION

The present invention relates to cyclic amine
5 derivatives for treating or preventing neuronal
damage associated with neurological diseases. The
invention also provides compositions comprising the
compounds of the present invention and methods of
utilizing those compositions for treating or
10 preventing neuronal damage.

BACKGROUND OF THE INVENTION

Neurological diseases are associated with the
death of or injury to neuronal cells. Typical
treatment of neurological diseases involves drugs
15 capable of inhibiting neuronal cell death. A more
recent approach involves the promotion of nerve
regeneration by promoting neuronal growth.

Neuronal growth, which is critical for the
survival of neurons, is stimulated *in vitro* by nerve
20 growth factors (NGF). For example, Glial Cell
Line-Derived Neurotrophic Factor (GDNF) demonstrates
neurotrophic activity both, *in vivo* and *in vitro*,
and is currently being investigated for the
treatment of Parkinson's disease. Insulin and
25 insulin-like growth factors have been shown to
stimulate growth of neurites in rat pheochromocytoma
PC12 cells and in cultured sympathetic and sensory
neurons [Recio-Pinto et al., J. Neurosci., 6, pp.
1211-1219 (1986)]. Insulin and insulin-like growth
30 factors also stimulate the regeneration of injured

-2-

motor nerves *in vivo* and *in vitro* [Near et al.,
Proc. Natl. Acad. Sci., pp. 89, 11716-11720 (1992);
and Edbladh et al., Brain Res., 641, pp. 76-82
(1994)]. Similarly, fibroblast growth factor (FGF)
5 stimulates neural proliferation [D. Gospodarowicz et
al., Cell Differ., 19, p. 1 (1986)] and growth [M.
A. Walter et al., Lymphokine Cytokine Res., 12, p.
135 (1993)].

There are, however, several disadvantages
10 associated with the use of nerve growth factors for
treating neurological diseases. They do not readily
cross the blood-brain barrier. They are unstable in
plasma and they have poor drug delivery properties.

Recently, small molecules have been shown to
15 stimulate neurite outgrowth *in vivo*. In individuals
suffering from a neurological disease, this
stimulation of neuronal growth protects neurons from
further degeneration, and accelerates the
regeneration of nerve cells. For example, estrogen
20 has been shown to promote the growth of axons and
dendrites, which are neurites sent out by nerve
cells to communicate with each other in a developing
or injured adult brain [(C. Dominique Toran-Allerand
et al., J. Steroid Biochem. Mol. Biol., 56, pp.
25 169-78 (1996); and B. S. McEwen et al., Brain Res.
Dev. Brain. Res., 87, pp. 91-95 (1995)]. The
progress of Alzheimer's disease is slowed in women
who take estrogen. Estrogen is hypothesized to
complement NGF and other neurotrophins and thereby
30 help neurons differentiate and survive.

-3-

Other target sites for the treatment of neurodegenerative disease are the immunophilin class of proteins. Immunophilins are a family of soluble proteins that mediate the actions of

5 immunosuppressant drugs such as cyclosporin A, FK506 and rapamycin. Of particular interest is the 12 kDa immunophilin, FK-506 binding protein (FKBP12). FKBP12 binds FK-506 and rapamycin, leading to an inhibition of T-cell activation and proliferation.

10 Interestingly, the mechanism of action of FK-506 and rapamycin are different. For a review, see, S. H. Solomon et al., Nature Med., 1, pp. 32-37 (1995). It has been reported that compounds with an affinity for FKBP12 that inhibit that protein's rotomase

15 activity possess nerve growth stimulatory activity. [Lyons et al., Proc. Natl. Acad. Sci. USA, 91, pp. 3191-3195 (1994)]. Many of these such compounds also have immunosuppressive activity.

FK506 (Tacrolimus) has been demonstrated to act

20 synergistically with NGF in stimulating neurite outgrowth in PC12 cells as well as sensory ganglia [Lyons et al. (1994)]. This compound has also been shown to be neuroprotective in focal cerebral ischemia [J. Sharkey and S. P. Butcher, Nature, 371,

25 pp. 336-339 (1994)] and to increase the rate of axonal regeneration in injured sciatic nerve [B. Gold et al., J. Neurosci., 15, pp. 7509-16 (1995)].

The use of immunosuppressive compounds, however, has drawbacks in that prolonged treatment

30 with these compounds can cause nephrotoxicity [Kopp et al., J. Am. Soc. Nephrol., 1, p. 162 (1991)],

-4-

neurological deficits [P.C. DeGroen et al., N. Eng. J. Med., 317, p. 861 (1987)] and vascular hypertension [Kahan et al., N. Eng. J. Med., 321, p. 1725 (1989)].

5 More recently, sub-classes of FKBP binding compounds which inhibit rotomase activity, but which purportedly lack immunosuppressive function have been disclosed for use in stimulating nerve growth [see, United States patent 5,614,547; WO 96/40633; 10 WO 96/40140; WO 97/16190; J. P. Steiner et al., Proc. Natl. Acad. Sci. USA, 94, pp. 2019-23 (1997); and G. S. Hamilton et al., Bioorg. Med. Chem. Lett., 7, pp. 1785-90 (1997)].


 Stimulation of neural axons in nerve cells by 15 piperidine derivatives is described in WO 96/41609. Clinical use of the piperidine and pyrrolidine derivatives known so far for stimulating axonal growth has not been promising, as the compounds are unstable in plasma and do not pass the blood-brain 20 barrier in adequate amounts.

 Though a wide variety of neurological degenerative diseases may be treated by promoting repair of neuronal damage, there are relatively few agents known to possess these properties. Thus, 25 there remains a need for new compounds and compositions that have the ability to either prevent or treat neuronal damage associated with neuropathologic.

SUMMARY OF THE INVENTION

30 The present invention provides compounds having formula (I):

-5-



and pharmaceutically acceptable derivatives thereof,
wherein:

X, when present, is O, S, or NR^1 ;

5 y is 0 or 1;

A, B and R^1 are independently E,

(C_1 - C_{10})-straight or branched alkyl, (C_2 - C_{10})-straight
or branched alkenyl or alkynyl, or (C_5 - C_7)-cycloalkyl
or cycloalkenyl; wherein 1 or 2 hydrogen atoms in
10 said alkyl, alkenyl or alkynyl are optionally and
independently replaced with E, (C_5 - C_7)-cycloalkyl or
cycloalkenyl; and wherein 1 to 2 of the $-\text{CH}_2-$ groups
in said alkyl, alkenyl, or alkynyl groups is
optionally and independently replaced by $-\text{O}-$, $-\text{S}-$,
15 $-\text{S}(\text{O})-$, $-\text{S}(\text{O})_2-$, $=\text{N}-$, $-\text{N}=$ or $-\text{N}(\text{R}^3)-$;

or, B and R^1 are independently hydrogen;

wherein R^3 is selected from hydrogen,

(C_1 - C_4)-straight or branched alkyl, (C_3 - C_4)-straight
or branched alkenyl or alkynyl, or (C_1 - C_4) bridging
20 alkyl, wherein a bridge is formed between the
nitrogen atom to which said R^3 is bound and any
carbon atom of said alkyl, alkenyl or alkynyl to
form a ring, and wherein said ring is optionally
benzofused;

25 wherein E is a saturated, partially saturated
or unsaturated, or aromatic monocyclic or bicyclic
ring system, wherein each ring comprises 5 to 7 ring

-6-

atoms independently selected from C, N, N(R³), O, S, S(O), or S(O)₂; and wherein no more than 4 ring atoms are selected from N, N(R³), O, S, S(O), or S(O)₂;

wherein 1 to 4 hydrogen atoms in E are

- 5 optionally and independently replaced with halogen, hydroxyl, hydroxymethyl, nitro, SO₃H, trifluoromethyl, trifluoromethoxy, (C₁-C₆)-straight or branched alkyl, (C₂-C₆)-straight or branched alkenyl, O-[(C₁-C₆)-straight or branched alkyl],
- 10 O-[(C₃-C₆)-straight or branched alkenyl], (CH₂)_n-N(R⁴)(R⁵), (CH₂)_n-NH(R⁴)-(CH₂)_n-Z, (CH₂)_n-N(R⁴-(CH₂)_n-Z)(R⁵-(CH₂)_n-Z), (CH₂)_n-Z, O-(CH₂)_n-Z, (CH₂)_n-O-Z, S-(CH₂)_n-Z, CH=CH-Z, 1,2-methylenedioxy, C(O)OH, C(O)O-[(C₁-C₆)-straight
- 15 or branched alkyl], C(O)O-(CH₂)_n-Z or C(O)-N(R⁴)(R⁵);

wherein each of R⁴ and R⁵ are independently hydrogen, (C₁-C₆)-straight or branched alkyl, (C₃-C₅)-straight or branched alkenyl, or wherein R⁴ and R⁵, when bound to the same nitrogen atom, are

20 taken together with the nitrogen atom to form a 5 or 6 membered ring, wherein said ring optionally contains 1 to 3 additional heteroatoms independently selected from N, N(R³), O, S, S(O), or S(O)₂; wherein said alkyl, alkenyl or alkynyl groups in R₄ and R₅

- 25 are optionally substituted with Z.

each n is independently 0 to 4;

- each Z is independently selected from a saturated, partially saturated or unsaturated, monocyclic or bicyclic ring system, wherein each
- 30 ring comprises 5 to 7 ring atoms independently selected from C, N, N(R³), O, S, S(O), or S(O)₂; and

-7-

wherein no more than 4 ring atoms are selected from N, N(R³), O, S, S(O), or S(O)₂;

wherein 1 to 4 hydrogen atoms in Z are optionally and independently replaced with halo, hydroxy, nitro, cyano, C(O)OH, (C₁-C₃)-straight or branched alkyl, O-(C₁-C₃)-straight or branched alkyl, C(O)O-[(C₁-C₃)-straight or branched alkyl], amino, NH[(C₁-C₃)-straight or branched alkyl], or N-[(C₁-C₃)-straight or branched alkyl]₂;

10 J is H, methyl, ethyl or benzyl; or wherein J is directly bound to a ring atom of ring Q to form with ring Q a fused bicyclic ring system, wherein the ring comprising J and the nitrogen atom to which J is bound is a 5-7 membered saturated or
15 unsaturated heterocyclic ring, optionally containing up to 3 additional heteroatoms selected from N, N(R³), O, S, S(O), or S(O)₂, wherein 1 to 4 hydrogen atoms in said ring comprising J are optionally and independently replaced with (C₁-C₆)-straight or
20 branched alkyl, (C₂-C₆)-straight or branched alkenyl or alkynyl, oxo, hydroxyl or Z; and wherein any -CH₂- group in said alkyl, alkenyl or alkynyl substituent is optionally and independently replaced by -O-, -S-, -S(O)-, -S(O₂)-, =N-, -N=, or -N(R³)-; and
25 wherein said ring comprising J is optionally fused with E;

wherein J, when not in a ring fused to ring Q, is optionally substituted with up to 3 substituents selected from halogen, OH, O-(C₁-C₆)-alkyl,
30 O-(CH₂)_n-Z, NO₂, C(O)OH, C(O)-O-(C₁-C₆)-alkyl, C(O)NR⁴R⁵, NR⁴R⁵ and (CH₂)_n-Z;

-8-

ring Q is a 5-7 membered saturated or unsaturated heterocyclic ring, optionally containing up to 3 additional heteroatoms selected from N, N(R³), O, S, S(O), or S(O)₂, wherein 1 to 4 hydrogen atoms in said heterocyclic ring are optionally and independently replaced with (C₁-C₆)-straight or branched alkyl, (C₂-C₆)-straight or branched alkenyl or alkynyl, oxo, hydroxyl or Z; and wherein any -CH₂- group in said alkyl, alkenyl or alkynyl substituent is optionally and independently replaced by -O-, -S-, -S(O)-, -S(O)₂-, =N-, -N=, or -N(R³)-; and wherein said heterocyclic ring is optionally fused with E;

G, when present, is -S(O)₂-, -C(O)-, -S(O)₂-Y-, -C(O)-Y-, -C(O)-C(O)-, or -C(O)-C(O)-Y-;

Y is oxygen, or N(R⁶);

wherein R⁶ is hydrogen, E, (C₁-C₆)-straight or branched alkyl, (C₃-C₆)-straight or branched alkenyl or alkynyl; or wherein R⁶ and D are taken together with the atoms to which they are bound to form a 5 to 7 membered ring system wherein said ring optionally contains 1 to 3 additional heteroatoms independently selected from N, N(R³), O, S, S(O), or S(O)₂; and wherein said ring is optionally benzofused;

D is hydrogen, (C₁-C₇)-straight or branched alkyl, (C₂-C₇)-straight or branched alkenyl or alkynyl, (C₅-C₇)-cycloalkyl or cycloalkenyl optionally substituted with (C₁-C₆)-straight or branched alkyl or (C₂-C₇)-straight or branched

-9-

alkenyl or alkynyl, [(C₁-C₇)-alkyl]-E,
[(C₂-C₇)-alkenyl or alkynyl]-E, or E;

wherein 1 to 2 of the CH₂ groups of said alkyl,
alkenyl or alkynyl chains in D is optionally
5 replaced by -O-, -S-, -S(O)-, -S(O₂)-, =N-, -N=, or -
N(R³);


provided that when J is hydrogen or G is
selected from -S(O)₂-, C(O)C(O)-, SO₂-Y, C(O)-Y, or
C(O)C(O)-Y, wherein Y is O; then D is not hydrogen;
10 m is 0 to 3; and
x is 0 or 1.

In another embodiment, the invention
provides
pharmaceutical compositions comprising the compounds
15 of formula (I). These compositions may be utilized
in methods treating various neurological diseases
which are influenced by neuronal regeneration and
axon growth or for stimulating neuronal regeneration
in an ex vivo nerve cell. Examples of such diseases
20 include peripheral nerve destruction due to physical
injury or diseases such as diabetes; physical
injuries to the central nervous system (e.g., brain
or spinal cord); stroke; neurological disturbances
due to nerve degeneration, such as Parkinson's
25 disease, Alzheimer's disease, and amyotrophic
lateral sclerosis.

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides compounds having
formula (I):

-10-



and pharmaceutically acceptable derivatives thereof,
wherein:

X, when present, is O, S, or NR¹;

5 y is 0 or 1;

A, B and R¹ are independently E,

(C₁-C₁₀)-straight or branched alkyl, (C₂-C₁₀)-straight
or branched alkenyl or alkynyl, or (C₅-C₇)-cycloalkyl
or cycloalkenyl; wherein 1 or 2 hydrogen atoms in
10 said alkyl, alkenyl or alkynyl are optionally and
independently replaced with E, (C₅-C₇)-cycloalkyl or
cycloalkenyl; and wherein 1 to 2 of the -CH₂- groups
in said alkyl, alkenyl, or alkynyl groups is
optionally and independently replaced by -O-, -S-,
15 -S(O)-, -S(O)₂-, =N-, -N= or -N(R³)-;

or, B and R¹ are independently hydrogen;

wherein R³ is selected from hydrogen,

(C₁-C₄)-straight or branched alkyl, (C₃-C₄)-straight
or branched alkenyl or alkynyl, or (C₁-C₄) bridging
20 alkyl, wherein a bridge is formed between the
nitrogen atom to which said R³ is bound and any
carbon atom of said alkyl, alkenyl or alkynyl to
form a ring, and wherein said ring is optionally
benzofused;

25 wherein E is a saturated, partially saturated
or unsaturated, or aromatic monocyclic or bicyclic
ring system, wherein each ring comprises 5 to 7 ring

-11-

atoms independently selected from C, N, N(R³), O, S, S(O), or S(O)₂; and wherein no more than 4 ring atoms are selected from N, N(R³), O, S, S(O), or S(O)₂;

wherein 1 to 4 hydrogen atoms in E are

- 5 optionally and independently replaced with halogen, hydroxyl, hydroxymethyl, nitro, SO₃H, trifluoromethyl, trifluoromethoxy, (C₁-C₆)-straight or branched alkyl, (C₂-C₆)-straight or branched alkenyl, O-[(C₁-C₆)-straight or branched alkyl],
- 10 O-[(C₃-C₆)-straight or branched alkenyl], (CH₂)_n-N(R⁴)(R⁵), (CH₂)_n-NH(R⁴)-(CH₂)_n-Z, (CH₂)_n-N(R⁴-(CH₂)_n-Z)(R⁵-(CH₂)_n-Z), (CH₂)_n-Z, O-(CH₂)_n-Z, (CH₂)_n-O-Z, S-(CH₂)_n-Z, CH=CH-Z, 1,2-methylenedioxy, C(O)OH, C(O)O-[(C₁-C₆)-straight
- 15 or branched alkyl], C(O)O-(CH₂)_n-Z or C(O)-N(R⁴)(R⁵);

wherein each of R⁴ and R⁵ are independently hydrogen, (C₁-C₆)-straight or branched alkyl, (C₃-C₅)-straight or branched alkenyl, or wherein R⁴ and R⁵, when bound to the same nitrogen atom, are

20 taken together with the nitrogen atom to form a 5 or 6 membered ring, wherein said ring optionally contains 1 to 3 additional heteroatoms independently selected from N, N(R³), O, S, S(O), or S(O)₂; wherein said alkyl, alkenyl or alkynyl groups in R₄ and R₅

25 are optionally substituted with Z.

each n is independently 0 to 4;

- each Z is independently selected from a saturated, partially saturated or unsaturated, monocyclic or bicyclic ring system, wherein each
- 30 ring comprises 5 to 7 ring atoms independently selected from C, N, N(R³), O, S, S(O), or S(O)₂; and

-12-

wherein no more than 4 ring atoms are selected from N, N(R³), O, S, S(O), or S(O)₂;

wherein 1 to 4 hydrogen atoms in Z are optionally and independently replaced with halo, hydroxy, nitro, cyano, C(O)OH, (C₁-C₃)-straight or branched alkyl, O-(C₁-C₃)-straight or branched alkyl, C(O)O-[(C₁-C₃)-straight or branched alkyl], amino, NH[(C₁-C₃)-straight or branched alkyl], or N-[(C₁-C₃)-straight or branched alkyl]₂;

10 J is H, methyl, ethyl or benzyl; or wherein J is directly bound to a ring atom of ring Q to form with ring Q a fused bicyclic ring system, wherein the ring comprising J and the nitrogen atom to which J is bound is a 5-7 membered saturated or
15 unsaturated heterocyclic ring, optionally containing up to 3 additional heteroatoms selected from N, N(R³), O, S, S(O), or S(O)₂, wherein 1 to 4 hydrogen atoms in said ring comprising J are optionally and independently replaced with (C₁-C₆)-straight or
20 branched alkyl, (C₂-C₆)-straight or branched alkenyl or alkynyl, oxo, hydroxyl or Z; and wherein any -CH₂- group in said alkyl, alkenyl or alkynyl substituent is optionally and independently replaced by -O-, -S-, -S(O)-, -S(O)₂-, =N-, -N=, or -N(R³)-; and
25 wherein said ring comprising J is optionally fused with E;

wherein J, when not in a ring fused to ring Q, is optionally substituted with up to 3 substituents selected from halogen, OH, O-(C₁-C₆)-alkyl,
30 O-(CH₂)_n-Z, NO₂, C(O)OH, C(O)-O-(C₁-C₆)-alkyl, C(O)NR⁴R⁵, NR⁴R⁵ and (CH₂)_n-Z;

-13-

ring Q is a 5-7 membered saturated or unsaturated heterocyclic ring, optionally containing up to 3 additional heteroatoms selected from N, N(R³), O, S, S(O), or S(O)₂, wherein 1 to 4 hydrogen atoms in said heterocyclic ring are optionally and independently replaced with (C₁-C₆)-straight or branched alkyl, (C₂-C₆)-straight or branched alkenyl or alkynyl, oxo, hydroxyl or Z; and wherein any -CH₂- group in said alkyl, alkenyl or alkynyl substituent is optionally and independently replaced by -O-, -S-, -S(O)-, -S(O)₂-, =N-, -N=, or -N(R³)-; and wherein said heterocyclic ring is optionally fused with E;

G, when present, is -S(O)₂-, -C(O)-, -S(O)₂-Y-, -C(O)-Y-, -C(O)-C(O)-, or -C(O)-C(O)-Y-;

Y is oxygen, or N(R⁶);

wherein R⁶ is hydrogen, E, (C₁-C₆)-straight or branched alkyl, (C₃-C₆)-straight or branched alkenyl or alkynyl; or wherein R⁶ and D are taken together with the atoms to which they are bound to form a 5 to 7 membered ring system wherein said ring optionally contains 1 to 3 additional heteroatoms independently selected from N, N(R³), O, S, S(O), or S(O)₂; and wherein said ring is optionally benzofused;

D is hydrogen, (C₁-C₇)-straight or branched alkyl, (C₂-C₇)-straight or branched alkenyl or alkynyl, (C₅-C₇)-cycloalkyl or cycloalkenyl optionally substituted with (C₁-C₆)-straight or branched alkyl or (C₂-C₇)-straight or branched

-14-

alkenyl or alkynyl, [(C₁-C₇)-alkyl]-E,
[(C₂-C₇)-alkenyl or alkynyl]-E, or E;

wherein 1 to 2 of the CH₂ groups of said alkyl,
alkenyl or alkynyl chains in D is optionally
5 replaced by -O-, -S-, -S(O)-, -S(O)₂-, =N-, -N=, or -
N(R³);

provided that when J is hydrogen or G is
selected from -S(O)₂-, C(O)C(O)-, SO₂-Y, C(O)-Y, or
C(O)C(O)-Y, wherein Y is O; then D is not hydrogen;
10 m is 0 to 3; and
x is 0 or 1.

According to a preferred embodiment, each
of A and B in formula (I) is (C₁-C₁₀) straight or
branched alkyl, wherein 1-2 hydrogen atoms in said
15 alkyl are optionally substituted with E.

In another preferred embodiment, B is
hydrogen.

According to another preferred embodiment,
each of A and B in formula (I) is -CH₂-CH₂-E or -
20 CH₂-CH₂-CH₂-E.

According to another preferred embodiment,
D in formula (I) is (C₁-C₇) straight or branched
alkyl, E or [(C₁-C₆)-straight or branched alkyl]-E.

According to a more preferred embodiment,
25 D is
an aromatic monocyclic or bicyclic ring system,
wherein each ring comprises 5-7 ring atoms
independently selected from C, N, N(R³), O, S, S(O),
or S(O)₂, and wherein no more than 4 ring atoms are
30 selected from N, N(R³), O, S, S(O), or S(O)₂.

According to an even more preferred

-15-

embodiment, D is phenyl or C₁-C₇ straight or branched alkyl group.

According to another preferred embodiment, E in formula (I) is a monocyclic or bicyclic

5 aromatic ring system, wherein said ring comprises 5-7 ring atoms independently selected from C, N, N(R³), O, S, S(O), or S(O)₂, and wherein 1 to 4 ring atoms are independently selected from N, N(R³), O, S, S(O), or S(O)₂.

10 Preferred embodiments of E include phenyl, naphthyl, indenyl, azulenyl, fluorenyl, anthracenyl, furyl, thienyl, pyridyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, isothiazolyl, 1,3,4-thiadiazolyl, 15 pyridazinyl, pyrimidinyl, 1,3,5-triazinyl, 1,3,5-trithianyl, benzo[b]furanyl, benzo[b]thiophenyl, purinyl, cinnolinyl, phthalazinyl, isoxazolyl, triazolyl, oxadiazolyl, pyrimidinyl, pyrazinyl, indolinyl, indolizinyl, 20 isoindolyl, benzimidazolyl, benzothiophenyl, quinolinyl, isoquinolinyl, quinazolinyl, quinoxalinyl, 1,8-naphthyridinyl, pteridinyl, carbazolyl, acridinyl, phnazinyl, phenothiazinyl, phenoxazinyl and benzothiazolyl, wherein E is 25 optionally substituted as described above.


More preferred embodiments of E include phenyl, furyl, thienyl, pyridyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, triazolyl, oxadiazolyl, pyrimidinyl, pyrazinyl, 30 indolyl, isoindolyl, benzimidazolyl, benzothiophenyl, quinolinyl, isoquinolinyl, and

-16-


benzothiazolyl, wherein E is optionally substituted as described above.

According to another preferred embodiment, J is H, methyl, ethyl or benzyl.

5 According to another preferred embodiment, Q is selected from any one of the following:



The most preferred compounds of formula
 10 (I) are set forth in Tables 1, below:
 Table 1.



#	D-(G) _x -	X-	A-	B-
1	CH ₃ -	NH-	3-pyrCH ₂ CH ₂ CH ₂ -	3-pyrCH ₂ CH ₂ CH ₂ -
2	CH ₃ CH ₂ -	NH-	3-pyrCH ₂ CH ₂ CH ₂ -	3-pyrCH ₂ CH ₂ CH ₂ -
3	C ₆ H ₅ CH ₂ -	NH-	3-pyrCH ₂ CH ₂ CH ₂ -	3-pyrCH ₂ CH ₂ CH ₂ -
4	CH ₃ C(=O)-	NH-	3-pyrCH ₂ CH ₂ CH ₂ -	3-pyrCH ₂ CH ₂ CH ₂ -
5	C ₆ H ₅ C(=O)-	NH-	3-pyrCH ₂ CH ₂ CH ₂ -	3-pyrCH ₂ CH ₂ CH ₂ -
6	C ₆ H ₅ CH ₂ OC(=O)-	NH-	3-pyrCH ₂ CH ₂ CH ₂ -	3-pyrCH ₂ CH ₂ CH ₂ -
7	C ₆ H ₅ C(=O)C(=O)-	NH-	3-pyrCH ₂ CH ₂ CH ₂ -	3-pyrCH ₂ CH ₂ CH ₂ -
8	CH ₃ -	C ₆ H ₅ CH ₂ N-	4-pyrCH ₂ CH ₂ -	4-pyrCH ₂ CH ₂ -
9	CH ₃ CH ₂ -	C ₆ H ₅ CH ₂ N-	4-pyrCH ₂ CH ₂ -	4-pyrCH ₂ CH ₂ -
10	C ₆ H ₅ CH ₂ -	C ₆ H ₅ CH ₂ N-	4-pyrCH ₂ CH ₂ -	4-pyrCH ₂ CH ₂ -
11	CH ₃ C(=O)-	C ₆ H ₅ CH ₂ N-	4-pyrCH ₂ CH ₂ -	4-pyrCH ₂ CH ₂ -
12	C ₆ H ₅ C(=O)-	C ₆ H ₅ CH ₂ N-	4-pyrCH ₂ CH ₂ -	4-pyrCH ₂ CH ₂ -

13	C ₆ H ₅ CH ₂ OC(=O)-	C ₆ H ₅ CH ₂ N-	4-pyrCH ₂ CH ₂ -	4-pyrCH ₂ CH ₂ -
14	C ₆ H ₅ C(=O)C(=O)-	C ₆ H ₅ CH ₂ N-	4-pyrCH ₂ CH ₂ -	4-pyrCH ₂ CH ₂ -
15	CH ₃ -	4-pyrCH ₂ N-	C ₆ H ₅ CH ₂ CH ₂ CH ₂ -	C ₆ H ₅ CH ₂ CH ₂ CH ₂ -
16	CH ₃ CH ₂ -	4-pyrCH ₂ N-	C ₆ H ₅ CH ₂ CH ₂ CH ₂ -	C ₆ H ₅ CH ₂ CH ₂ CH ₂ -
17	C ₆ H ₅ CH ₂ -	4-pyrCH ₂ N-	C ₆ H ₅ CH ₂ CH ₂ CH ₂ -	C ₆ H ₅ CH ₂ CH ₂ CH ₂ -
18	CH ₃ C(=O)-	4-pyrCH ₂ N-	C ₆ H ₅ CH ₂ CH ₂ CH ₂ -	C ₆ H ₅ CH ₂ CH ₂ CH ₂ -
19	C ₆ H ₅ C(=O)-	4-pyrCH ₂ N-	C ₆ H ₅ CH ₂ CH ₂ CH ₂ -	C ₆ H ₅ CH ₂ CH ₂ CH ₂ -
20	C ₆ H ₅ CH ₂ OC(=O)-	4-pyrCH ₂ N-	C ₆ H ₅ CH ₂ CH ₂ CH ₂ -	C ₆ H ₅ CH ₂ CH ₂ CH ₂ -
21	C ₆ H ₅ C(=O)C(=O)-	4-pyrCH ₂ N-	C ₆ H ₅ CH ₂ CH ₂ CH ₂ -	C ₆ H ₅ CH ₂ CH ₂ CH ₂ -


The compounds of formula (I) may be stereoisomers, geometric isomers or stable tautomers. The invention envisions all possible isomers, such as E and Z isomers, S and R enantiomers, diastereoisomers, racemates, and mixtures of those. It is preferred that the substituent in the 2 position have the S configuration.

The compounds of the present invention may be readily prepared using known synthetic methods. For example, compounds of formula (I) may be prepared as shown below in Scheme I and II:

The compounds of the present invention may be readily prepared using known synthetic methods. For example, compounds of formula (I) may be prepared as shown below in Scheme I (wherein y in (X)_y is 1) and Scheme II (wherein y in (X)_y is 0):


Scheme I

-18-



-19-

Scheme II



; wherein

PG is a protecting group; LG is a leaving group and
 Li is lithium. In each of these schemes, the
 5 initial step involves the coupling of the compounds,
 followed by removal of the protecting group (PG).

One of skill in the art will be well aware
 of

analogous synthetic methods for preparing compounds
 10 of formula (I).

-20-

According to another embodiment, this invention provides compositions comprising a compound of formula (I) and a pharmaceutically acceptable carrier.

Pharmaceutically acceptable carriers that may be used in these pharmaceutical compositions include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxy methylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, polyethylene glycol and wool fat.

In another embodiment, the pharmaceutical composition of the present invention is comprised of a compound of formula (I), a pharmaceutically acceptable carrier, and a neurotrophic factor.

The term "neurotrophic factor," as used herein, refers to compounds which are capable of stimulating growth or proliferation of nervous tissue. Numerous neurotrophic factors have been identified in the art and any of those factors may be utilized in the compositions of this invention.

-21-

These neurotrophic factors include, but are not limited to, nerve growth factor (NGF), insulin-like growth factor (IGF-1) and its active truncated derivatives such as gIGF-1 and Des(1-3)IGF-I, acidic
5 and basic fibroblast growth factor (aFGF and bFGF, respectively), platelet-derived growth factors (PDGF), brain-derived neurotrophic factor (BDNF), ciliary neurotrophic factors (CNTF), glial cell line-derived neurotrophic factor (GDNF),
10 neurotrophin-3 (NT-3) and neurotrophin 4/5 (NT-4/5). The most preferred neurotrophic factor in the compositions of this invention is NGF.

As used herein, the described compounds used in the pharmaceutical compositions and methods
15 of this invention, are defined to include pharmaceutically acceptable derivatives thereof. A "pharmaceutically acceptable derivative" denotes any pharmaceutically acceptable salt, ester, or salt of such ester, of a compound of this invention or any
20 other compound which, upon administration to a patient, is capable of providing (directly or indirectly) a compound of this invention, or a metabolite or residue thereof, characterized by the ability to promote repair or prevent damage of
25 neurons from disease or physical trauma.

If pharmaceutically acceptable salts of the described compounds are used, those salts are preferably derived from inorganic or organic acids and bases. Included among such acid salts are the
30 following: acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate,

-22-

citrate, camphorate, camphorsulfonate,
cyclopentanepropionate, digluconate, dodecylsulfate,
ethanesulfonate, fumarate, glucoheptanoate,
glycerophosphate, hemisulfate, heptanoate,
5 hexanoate, hydrochloride, hydrobromide, hydroiodide,
2-hydroxyethanesulfonate, lactate, maleate,
methanesulfonate, 2-naphthalenesulfonate,
nicotinate, oxalate, palmoate, pectinate,
persulfate, 3-phenyl-propionate, picrate, pivalate,
10 propionate, succinate, tartrate, thiocyanate,
tosylate and undecanoate. Base salts include
ammonium salts, alkali metal salts, such as sodium
and potassium salts, alkaline earth metal salts,
such as calcium and magnesium salts, salts with
15 organic bases, such as dicyclohexylamine salts,
N-methyl-D-glucamine, and salts with amino acids
such as arginine, lysine, and so forth. Also, the
basic nitrogen-containing groups can be quaternized
with such agents as lower alkyl halides, such as
20 methyl, ethyl, propyl, and butyl chloride, bromides
and iodides; dialkyl sulfates, such as dimethyl,
diethyl, dibutyl and diamyl sulfates, long chain
halides such as decyl, lauryl, myristyl and stearyl
chlorides, bromides and iodides, aralkyl halides,
25 such as benzyl and phenethyl bromides and others.
Water or oil-soluble or dispersible products are
thereby obtained.

The described compounds utilized in the
compositions and methods of this invention may also
30 be modified by appending appropriate functionalities
to enhance selective biological properties. Such

-23-

modifications are known in the art and include those which increase biological penetration into a given biological system (e.g., blood, lymphatic system, central nervous system), increase oral availability, 5 increase solubility to allow administration by injection, alter metabolism and alter rate of excretion.

The compositions of the present invention may be administered orally, parenterally, by 10 inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir. The term "parenteral" as used herein includes subcutaneous, intravenous, intramuscular, intra-articular, intra-synovial, intrasternal, 15 intrathecal, intrahepatic, intralesional and intracranial injection or infusion techniques. Preferably, the compositions are administered orally, intraperitoneally or intravenously.

Sterile injectable forms of the 20 compositions of this invention may be aqueous or oleaginous suspension. These suspensions may be formulated according to techniques known in the art using suitable dispersing or wetting agents and suspending agents. The sterile injectable 25 preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are 30 water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils

-24-

are conventionally employed as a solvent or suspending medium. For this purpose, any bland fixed oil may be employed including synthetic mono- or di-glycerides. Fatty acids, such as oleic acid and its glyceride derivatives are useful in the preparation of injectables, as are natural pharmaceutically-acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions. These oil solutions or suspensions may also contain a long-chain alcohol diluent or dispersant, such as Ph. Helv or similar alcohol.

The pharmaceutical compositions of this invention may be orally administered in any orally acceptable dosage form including, but not limited to, capsules, tablets, aqueous suspensions or solutions. In the case of tablets for oral use, carriers which are commonly used include lactose and corn starch. Lubricating agents, such as magnesium stearate, are also typically added. For oral administration in a capsule form, useful diluents include lactose and dried corn starch. When aqueous suspensions are required for oral use, the active ingredient is combined with emulsifying and suspending agents. If desired, certain sweetening, flavoring or coloring agents may also be added.

Alternatively, the pharmaceutical compositions of this invention may be administered in the form of suppositories for rectal administration. These can be prepared by mixing the agent with a suitable non-irritating excipient which is solid at room temperature but liquid at rectal

-25-

temperature and therefore will melt in the rectum to release the drug. Such materials include cocoa butter, beeswax and polyethylene glycols.

The pharmaceutical compositions of this invention may also be administered topically, especially when the target of treatment includes areas or organs readily accessible by topical application, including diseases of the eye, the skin, or the lower intestinal tract. Suitable topological formulations are readily prepared for each of these areas or organs.

Topical application for the lower intestinal tract can be effected in a rectal suppository formulation (see above) or in a suitable enema formulation. Topically-transdermal patches may also be used.

For topical applications, the pharmaceutical compositions may be formulated in a suitable ointment containing the active component suspended or dissolved in one or more carriers. Carriers for topical administration of the compounds of this invention include, but are not limited to, mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene, polyoxypropylene compound, emulsifying wax and water. Alternatively, the pharmaceutical compositions can be formulated in a suitable lotion or cream containing the active components suspended or dissolved in one or more pharmaceutically acceptable carriers. Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl

-26-

esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water.

For ophthalmic use, the pharmaceutical compositions may be formulated as micronized
5 suspensions in isotonic, pH adjusted sterile saline, or, preferably, as solutions in isotonic, pH adjusted sterile saline, either with or without a preservative such as benzylalkonium chloride. Alternatively, for ophthalmic uses, the
10 pharmaceutical compositions may be formulated in an ointment such as petrolatum.

The pharmaceutical compositions of this invention may also be administered by nasal aerosol or inhalation. Such compositions are prepared
15 according to techniques well-known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or
20 other conventional solubilizing or dispersing agents.

The amount of both a described compound and the optional neurotrophic factor that may be combined with the carrier materials to produce a
25 single dosage form will vary depending upon the host treated and the particular mode of administration. Preferably, the compositions should be formulated so that a dosage of between 0.01 - 100 mg/kg body weight/day of the described compound can be
30 administered. If a neurotrophic factor is present in the composition, then a dosage of between 0.01 µg

-27-

- 100 mg/kg body weight/day of the neurotrophic factor can be administered to a patient receiving these compositions.

It should also be understood that a
5 specific dosage and treatment regimen for any particular patient will depend upon a variety of factors, including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, rate of
10 excretion, drug combination, and the judgment of the treating physician and the severity of the particular disease being treated. The amount of active ingredients will also depend upon the particular described compound and neurotrophic
15 factor in the composition.

According to another embodiment, this invention provides methods for promoting repair or preventing neuronal damage or neurodegeneration *in vivo* or in an *ex vivo* nerve cell. Such methods
20 comprise the step of treating nerve cells with any of the compounds described above. Preferably, this method promotes repair or prevents neuronal damage in a patient, and the compound is formulated into a composition additionally comprising a
25 pharmaceutically acceptable carrier. The amount of the compound utilized in these methods is between about 0.01 and 100 mg/kg body weight/day.

According to an alternate embodiment, the method of promoting repair or preventing neuronal
30 damage comprises the additional step of treating nerve cells with a neurotrophic factor, such as

-28-

those contained in the pharmaceutical compositions of this invention. This embodiment includes administering the compound and the neurotrophic agent in a single dosage form or in separate, multiple dosage forms. If separate dosage forms are utilized, they may be administered concurrently, consecutively or within less than about 5 hours of one another.

Preferably, the methods of this invention are used to stimulate axonal growth in nerve cells. The compounds are, therefore, suitable for treating or preventing neuronal damage caused by a wide variety of diseases or physical traumas. These include, but are not limited to, Alzheimer's disease, Parkinson's disease, ALS, Huntington's disease, Tourette's syndrome, stroke and ischemia associated with stroke, neural paropathy, other neural degenerative diseases, motor neuron diseases, sciatic crush, spinal cord injuries and facial nerve crush.

In a particularly preferred embodiment of the invention, the method is used to treat a patient suffering from trigeminal neuralgia, glossopharyngeal neuralgia, Bell's Palsy, myasthenia gravis, muscular dystrophy, muscle injury, progressive muscular atrophy, progressive bulbar inherited muscular atrophy, herniated, ruptured, or prolapsed intervertebrae disk syndrome's, cervical spondylosis, plexus disorders, thoracic outlet destruction syndromes, peripheral neuropathies, such as those caused by lead, dapsone, ticks, or porphyria, other peripheral myelin disorders, Alzheimer's disease,

-29-

Gullain-Barre syndrome, Parkinson's disease and other Parkinsonian disorders, ALS, Tourette's syndrome, multiple sclerosis, other central myelin disorders, stroke and ischemia associated with
5 stroke, neural paropathy, other neural degenerative diseases, motor neuron diseases, sciatic crush, neuropathy associated with diabetes, spinal cord injuries, facial nerve crush and other trauma, chemotherapy- and other medication-induced
10 neuropathies, and Huntington's disease.

More preferably, the compositions of the present invention are used for treating Parkinson's disease, amyotrophic lateral sclerosis, Alzheimer's disease, stroke, neuralgias, muscular atrophies, and
15 Guillain-Barré syndrome.

For use of the compounds according to the invention as medications, they are administered in the form of a pharmaceutical preparation containing not only the active ingredient but also carriers,
20 auxiliary substances, and/or additives suitable for enteric or parenteral administration.

Administration can be oral or sublingual as a solid in the form of capsules or tablets, as a liquid in the form of solutions, suspensions, elixirs,
25 aerosols or emulsions, or rectal in the form of suppositories, or in the form of solutions for injection which can be given subcutaneously, intramuscularly, or intravenously, or which can be given topically or intrathecally. Auxiliary
30 substances for the desired medicinal formulation include the inert organic and inorganic carriers

-30-

known to those skilled in the art, such as water, gelatin, gum arabic, lactose, starches, magnesium stearate, talc, vegetable oils, polyalkylene glycols, etc. The medicinal formulations may also
5 contain preservatives, stabilizers, wetting agents, emulsifiers, or salts to change the osmotic pressure or as buffers.

Solutions or suspensions for injection are suitable for parenteral administration, and
10 especially aqueous solutions of the active compounds in polyhydroxy-ethoxylated castor oil.

Surface-active auxiliary substances such as salts of gallic acid, animal or vegetable
15 phospholipids, or mixtures of them, and liposomes or their components, can be used as carrier systems.


The neurotrophic effect of the compounds of formula (I) of the present invention and their
20 physiologically acceptable salts can be determined by the methods of W. E. Lyons et al., Proc. Natl. Acad. Sci. USA, Vol. 91, pp. 3191-3195 (1994) and W. E. Lyons et al., Proc. Natl. Acad. Sci. USA, Vol. 91, pages 3191-3195 (1994), the disclosures of which
25 are herein incorporated by reference.

In order that this invention be more fully understood, the following examples are set forth. These examples are for the purpose of illustration only and are not to be construed as limiting the
30 scope of the invention in any way.

-31-

EXAMPLE 1

Compounds 1-21 are tabulated below and have the general formula:



#	D-(G) _x -	X-	A-	B-
1	CH ₃ -	NH-	3-pyrCH ₂ CH ₂ CH ₂ -	3-pyrCH ₂ CH ₂ CH ₂ -
2	CH ₃ CH ₂ -	NH-	3-pyrCH ₂ CH ₂ CH ₂ -	3-pyrCH ₂ CH ₂ CH ₂ -
3	C ₆ H ₅ CH ₂ -	NH-	3-pyrCH ₂ CH ₂ CH ₂ -	3-pyrCH ₂ CH ₂ CH ₂ -
4	CH ₃ C(=O)-	NH-	3-pyrCH ₂ CH ₂ CH ₂ -	3-pyrCH ₂ CH ₂ CH ₂ -
5	C ₆ H ₅ C(=O)-	NH-	3-pyrCH ₂ CH ₂ CH ₂ -	3-pyrCH ₂ CH ₂ CH ₂ -
6	C ₆ H ₅ CH ₂ OC(=O)-	NH-	3-pyrCH ₂ CH ₂ CH ₂ -	3-pyrCH ₂ CH ₂ CH ₂ -
7	C ₆ H ₅ C(=O)C(=O)-	NH-	3-pyrCH ₂ CH ₂ CH ₂ -	3-pyrCH ₂ CH ₂ CH ₂ -
8	CH ₃ -	C ₆ H ₅ CH ₂ N-	4-pyrCH ₂ CH ₂ -	4-pyrCH ₂ CH ₂ -
9	CH ₃ CH ₂ -	C ₆ H ₅ CH ₂ N-	4-pyrCH ₂ CH ₂ -	4-pyrCH ₂ CH ₂ -
10	C ₆ H ₅ CH ₂ -	C ₆ H ₅ CH ₂ N-	4-pyrCH ₂ CH ₂ -	4-pyrCH ₂ CH ₂ -
11	CH ₃ C(=O)-	C ₆ H ₅ CH ₂ N-	4-pyrCH ₂ CH ₂ -	4-pyrCH ₂ CH ₂ -
12	C ₆ H ₅ C(=O)-	C ₆ H ₅ CH ₂ N-	4-pyrCH ₂ CH ₂ -	4-pyrCH ₂ CH ₂ -
13	C ₆ H ₅ CH ₂ OC(=O)-	C ₆ H ₅ CH ₂ N-	4-pyrCH ₂ CH ₂ -	4-pyrCH ₂ CH ₂ -
14	C ₆ H ₅ C(=O)C(=O)-	C ₆ H ₅ CH ₂ N-	4-pyrCH ₂ CH ₂ -	4-pyrCH ₂ CH ₂ -
15	CH ₃ -	4-pyrCH ₂ N-	C ₆ H ₅ CH ₂ CH ₂ CH ₂ -	C ₆ H ₅ CH ₂ CH ₂ CH ₂ -
16	CH ₃ CH ₂ -	4-pyrCH ₂ N-	C ₆ H ₅ CH ₂ CH ₂ CH ₂ -	C ₆ H ₅ CH ₂ CH ₂ CH ₂ -
17	C ₆ H ₅ CH ₂ -	4-pyrCH ₂ N-	C ₆ H ₅ CH ₂ CH ₂ CH ₂ -	C ₆ H ₅ CH ₂ CH ₂ CH ₂ -
18	CH ₃ C(=O)-	4-pyrCH ₂ N-	C ₆ H ₅ CH ₂ CH ₂ CH ₂ -	C ₆ H ₅ CH ₂ CH ₂ CH ₂ -
19	C ₆ H ₅ C(=O)-	4-pyrCH ₂ N-	C ₆ H ₅ CH ₂ CH ₂ CH ₂ -	C ₆ H ₅ CH ₂ CH ₂ CH ₂ -
20	C ₆ H ₅ CH ₂ OC(=O)-	4-pyrCH ₂ N-	C ₆ H ₅ CH ₂ CH ₂ CH ₂ -	C ₆ H ₅ CH ₂ CH ₂ CH ₂ -
21	C ₆ H ₅ C(=O)C(=O)-	4-pyrCH ₂ N-	C ₆ H ₅ CH ₂ CH ₂ CH ₂ -	C ₆ H ₅ CH ₂ CH ₂ CH ₂ -


-32-

While we have hereinbefore presented a number of embodiments of this invention, it is apparent that our basic construction may be altered to provide other embodiments which utilize the products, processes and methods of this invention. Therefore, it will be appreciated that the scope of this invention is to be defined by the appended claims, rather than by the specific embodiments which have been presented by way of example.

-33-

CLAIMS

1. A compound having formula (I):



and pharmaceutically acceptable derivatives thereof,
wherein:

X, when present, is O, S, or NR^1 ;

y is 0 or 1;

A, B and R^1 are independently E,

(C_1 - C_{10})-straight or branched alkyl, (C_2 - C_{10})-straight or branched alkenyl or alkynyl, or (C_5 - C_7)-cycloalkyl or cycloalkenyl; wherein 1 or 2 hydrogen atoms in said alkyl, alkenyl or alkynyl are optionally and independently replaced with E, (C_5 - C_7)-cycloalkyl or cycloalkenyl; and wherein 1 to 2 of the $-\text{CH}_2-$ groups in said alkyl, alkenyl, or alkynyl groups is optionally and independently replaced by $-\text{O}-$, $-\text{S}-$, $-\text{S}(\text{O})-$, $-\text{S}(\text{O})_2-$, $=\text{N}-$, $-\text{N}=-$ or $-\text{N}(\text{R}^3)-$;

or, B and R^1 are independently hydrogen;

wherein R^3 is selected from hydrogen,

(C_1 - C_4)-straight or branched alkyl, (C_3 - C_4)-straight or branched alkenyl or alkynyl, or (C_1 - C_4) bridging alkyl, wherein a bridge is formed between the nitrogen atom to which said R^3 is bound and any carbon atom of said alkyl, alkenyl or alkynyl to form a ring, and wherein said ring is optionally benzofused;

wherein E is a saturated, partially saturated

-34-

or unsaturated, or aromatic monocyclic or bicyclic ring system, wherein each ring comprises 5 to 7 ring atoms independently selected from C, N, N(R³), O, S, S(O), or S(O)₂; and wherein no more than 4 ring atoms are selected from N, N(R³), O, S, S(O), or S(O)₂;

wherein 1 to 4 hydrogen atoms in E are optionally and independently replaced with halogen, hydroxyl, hydroxymethyl, nitro, SO₃H, trifluoromethyl, trifluoromethoxy, (C₁-C₆)-straight or branched alkyl, (C₂-C₆)-straight or branched alkenyl, O-[(C₁-C₆)-straight or branched alkyl], O-[(C₃-C₆)-straight or branched alkenyl], (CH₂)_n-N(R⁴)(R⁵), (CH₂)_n-NH(R⁴)-(CH₂)_n-Z, (CH₂)_n-N(R⁴)-(CH₂)_n-Z (R⁵-(CH₂)_n-Z), (CH₂)_n-Z, O-(CH₂)_n-Z, (CH₂)_n-O-Z, S-(CH₂)_n-Z, CH=CH-Z, 1,2-methylenedioxy, C(O)OH, C(O)O-[(C₁-C₆)-straight or branched alkyl], C(O)O-(CH₂)_n-Z or C(O)-N(R⁴)(R⁵);

wherein each of R⁴ and R⁵ are independently hydrogen, (C₁-C₆)-straight or branched alkyl, (C₃-C₅)-straight or branched alkenyl, or wherein R⁴ and R⁵, when bound to the same nitrogen atom, are taken together with the nitrogen atom to form a 5 or 6 membered ring, wherein said ring optionally contains 1 to 3 additional heteroatoms independently selected from N, N(R³), O, S, S(O), or S(O)₂; wherein said alkyl, alkenyl or alkynyl groups in R₄ and R₅ are optionally substituted with Z.

each n is independently 0 to 4;

each Z is independently selected from a saturated, partially saturated or unsaturated, monocyclic or bicyclic ring system, wherein each

-35-

ring comprises 5 to 7 ring atoms independently selected from C, N, N(R³), O, S, S(O), or S(O)₂; and wherein no more than 4 ring atoms are selected from N, N(R³), O, S, S(O), or S(O)₂;

wherein 1 to 4 hydrogen atoms in Z are optionally and independently replaced with halo, hydroxy, nitro, cyano, C(O)OH, (C₁-C₃)-straight or branched alkyl, O-(C₁-C₃)-straight or branched alkyl, C(O)O-[(C₁-C₃)-straight or branched alkyl], amino, NH[(C₁-C₃)-straight or branched alkyl], or N-[(C₁-C₃)-straight or branched alkyl]₂;

J is H, methyl, ethyl or benzyl; or wherein J is directly bound to a ring atom of ring Q to form with ring Q a fused bicyclic ring system, wherein the ring comprising J and the nitrogen atom to which J is bound is a 5-7 membered saturated or unsaturated heterocyclic ring, optionally containing up to 3 additional heteroatoms selected from N, N(R³), O, S, S(O), or S(O)₂, wherein 1 to 4 hydrogen atoms in said ring comprising J are optionally and independently replaced with (C₁-C₆)-straight or branched alkyl, (C₂-C₆)-straight or branched alkenyl or alkynyl, oxo, hydroxyl or Z; and wherein any -CH₂- group in said alkyl, alkenyl or alkynyl substituent is optionally and independently replaced by -O-, -S-, -S(O)-, -S(O)₂-, =N-, -N=, or -N(R³)-; and wherein said ring comprising J is optionally fused with E;

wherein J, when not in a ring fused to ring Q, is optionally substituted with up to 3 substituents selected from halogen, OH, O-(C₁-C₆)-alkyl,

-36-

O-(CH₂)_n-Z, NO₂, C(O)OH, C(O)-O-(C₁-C₆)-alkyl,
C(O)NR⁴R⁵, NR⁴R⁵ and (CH₂)_n-Z;

ring Q is a 5-7 membered saturated or unsaturated heterocyclic ring, optionally containing up to 3 additional heteroatoms selected from N, N(R³), O, S, S(O), or S(O)₂, wherein 1 to 4 hydrogen atoms in said heterocyclic ring are optionally and independently replaced with (C₁-C₆)-straight or branched alkyl, (C₂-C₆)-straight or branched alkenyl or alkynyl, oxo, hydroxyl or Z; and wherein any -CH₂- group in said alkyl, alkenyl or alkynyl substituent is optionally and independently replaced by -O-, -S-, -S(O)-, -S(O)₂-, =N-, -N=, or -N(R³)-; and wherein said heterocyclic ring is optionally fused with E;

G, when present, is -S(O)₂-, -C(O)-, -S(O)₂-Y-, -C(O)-Y-, -C(O)-C(O)-, or -C(O)-C(O)-Y-;

Y is oxygen, or N(R⁶);

wherein R⁶ is hydrogen, E, (C₁-C₆)-straight or branched alkyl, (C₃-C₆)-straight or branched alkenyl or alkynyl; or wherein R⁶ and D are taken together with the atoms to which they are bound to form a 5 to 7 membered ring system wherein said ring optionally contains 1 to 3 additional heteroatoms independently selected from N, N(R³), O, S, S(O), or S(O)₂; and wherein said ring is optionally benzofused;

D is hydrogen, (C₁-C₇)-straight or branched alkyl, (C₂-C₇)-straight or branched alkenyl or alkynyl, (C₅-C₇)-cycloalkyl or cycloalkenyl optionally substituted with (C₁-C₆)-straight or

-37-

branched alkyl or (C₂-C₇)-straight or branched alkenyl or alkynyl, [(C₁-C₇)-alkyl]-E, [(C₂-C₇)-alkenyl or alkynyl]-E, or E;

wherein 1 to 2 of the CH₂ groups of said alkyl, alkenyl or alkynyl chains in D is optionally replaced by -O-, -S-, -S(O)-, -S(O)₂-, =N-, -N=, or -N(R³);

provided that when J is hydrogen or G is selected from -S(O)₂-, C(O)C(O)-, SO₂-Y, C(O)-Y, or C(O)C(O)-Y, wherein Y is O; then D is not hydrogen;

m is 0 to 3; and

x is 0 or 1.

2. The compound according to claim 1, wherein:

each of A and B is independently selected from -CH₂-CH₂-E or -CH₂-CH₂-CH₂-E; and

E is a monocyclic or bicyclic aromatic ring system, wherein said ring comprises 5-7 ring atoms independently selected from C, N, N(R³), O, S, S(O), or S(O)₂, and wherein 1 to 4 ring atoms are independently selected from N, N(R³), O, S, S(O), or S(O)₂;

wherein 1 to 4 hydrogen atoms in E are optionally and independently replaced with halogen, hydroxyl, hydroxymethyl, nitro, SO₃H, trifluoromethyl, trifluoromethoxy, (C₁-C₆)-straight or branched alkyl, (C₂-C₆)-straight or branched alkenyl, O-[(C₁-C₆)-straight or branched alkyl], O-[(C₃-C₆)-straight or branched alkenyl], (CH₂)_n-N(R⁴)(R⁵), (CH₂)_n-NH(R⁴)-(CH₂)_n-Z, (CH₂)_n-N(R⁴-(CH₂)_n-Z)(R⁵-(CH₂)_n-Z), (CH₂)_n-Z,

-38-

O-(CH₂)_n-Z, (CH₂)_n-O-Z, S-(CH₂)_n-Z, CH=CH-Z,
1,2-methylenedioxy, C(O)OH, or C(O)-N(R⁴)(R⁵).

3. The compound according to claim 1 or 2, wherein D is an aromatic monocyclic or bicyclic ring system, wherein each ring comprises 5 to 7 ring atoms independently selected from C, N, N(R³), O, S, S(O), or S(O)₂; and wherein no more than 4 ring atoms are selected from N, N(R³), O, S, S(O), or S(O)₂.

4. The compound according to claim 3, wherein:

D is phenyl; and
x is 1.

5. The compound according to claim 4, wherein G is -C(O)C(O)-.

6. The compound according to claim 4, wherein G is -SO₂-.

7. The compound according to claim 4, wherein G is -C(O)-.

8. The compound according to claim 4, wherein G is -C(O)Y-.

9. The compound according to claim 1 or 2, wherein:

x is 0;

-39-

D is selected from (C₁-C₅)-straight or branched alkyl, or [(C₁-C₃)-straight or branched alkyl)]-E; and


E is an aromatic monocyclic or bicyclic ring system, wherein in said ring system each ring comprises 5 to 7 ring atoms independently selected from C, N, N(R³), O, S, S(O), or S(O)₂; and wherein no more than 4 ring atoms are selected from N, N(R³), O, S, S(O), or S(O)₂.

10. The compound according to claim 9, wherein E is phenyl.

11. The compound according to claim 2, wherein each of A and B is independently selected from -CH₂-CH₂-E or -CH₂-CH₂-CH₂-E; and E is pyridyl.

12. The compound according to claim 1, wherein said compound is selected from any one of compounds 1-21 in Table 1 as follows.

Table 1



#	D-(G) _x -	X-	A-	B-
1	CH ₃ -	NH-	3-pyrCH ₂ CH ₂ CH ₂ -	3-pyrCH ₂ CH ₂ CH ₂ -
2	CH ₃ CH ₂ -	NH-	3-pyrCH ₂ CH ₂ CH ₂	3-pyrCH ₂ CH ₂ CH ₂
3	C ₆ H ₅ CH ₂ -	NH-	3-pyrCH ₂ CH ₂ CH ₂	3-pyrCH ₂ CH ₂ CH ₂
4	CH ₃ C(=O)-	NH-	3-pyrCH ₂ CH ₂ CH ₂	3-pyrCH ₂ CH ₂ CH ₂
5	C ₆ H ₅ C(=O)-	NH-	3-pyrCH ₂ CH ₂ CH ₂	3-pyrCH ₂ CH ₂ CH ₂
6	C ₆ H ₅ CH ₂ OC(=O)-	NH-	3-pyrCH ₂ CH ₂ CH ₂	3-pyrCH ₂ CH ₂ CH ₂

7	C ₆ H ₅ C(=O)C(=O)-	NH-	3-pyrCH ₂ CH ₂ CH ₂	3-pyrCH ₂ CH ₂ CH ₂
8	CH ₃ -	C ₆ H ₅ CH ₂ N-	4-pyrCH ₂ CH ₂ -	4-pyrCH ₂ CH ₂ -
9	CH ₃ CH ₂ -	C ₆ H ₅ CH ₂ N-	4-pyrCH ₂ CH ₂ -	4-pyrCH ₂ CH ₂ -
10	C ₆ H ₅ CH ₂ -	C ₆ H ₅ CH ₂ N-	4-pyrCH ₂ CH ₂ -	4-pyrCH ₂ CH ₂ -
11	CH ₃ C(=O)-	C ₆ H ₅ CH ₂ N-	4-pyrCH ₂ CH ₂ -	4-pyrCH ₂ CH ₂ -
12	C ₆ H ₅ C(=O)-	C ₆ H ₅ CH ₂ N-	4-pyrCH ₂ CH ₂ -	4-pyrCH ₂ CH ₂ -
13	C ₆ H ₅ CH ₂ OC(=O)-	C ₆ H ₅ CH ₂ N-	4-pyrCH ₂ CH ₂ -	4-pyrCH ₂ CH ₂ -
14	C ₆ H ₅ C(=O)C(=O)-	C ₆ H ₅ CH ₂ N-	4-pyrCH ₂ CH ₂ -	4-pyrCH ₂ CH ₂ -
15	CH ₃ -	4-pyrCH ₂ N-	C ₆ H ₅ CH ₂ CH ₂ CH ₂ -	C ₆ H ₅ CH ₂ CH ₂ CH ₂ -
16	CH ₃ CH ₂ -	4-pyrCH ₂ N-	C ₆ H ₅ CH ₂ CH ₂ CH ₂ -	C ₆ H ₅ CH ₂ CH ₂ CH ₂ -
17	C ₆ H ₅ CH ₂ -	4-pyrCH ₂ N-	C ₆ H ₅ CH ₂ CH ₂ CH ₂ -	C ₆ H ₅ CH ₂ CH ₂ CH ₂ -
18	CH ₃ C(=O)-	4-pyrCH ₂ N-	C ₆ H ₅ CH ₂ CH ₂ CH ₂ -	C ₆ H ₅ CH ₂ CH ₂ CH ₂ -
19	C ₆ H ₅ C(=O)-	4-pyrCH ₂ N-	C ₆ H ₅ CH ₂ CH ₂ CH ₂ -	C ₆ H ₅ CH ₂ CH ₂ CH ₂ -
20	C ₆ H ₅ CH ₂ OC(=O)-	4-pyrCH ₂ N-	C ₆ H ₅ CH ₂ CH ₂ CH ₂ -	C ₆ H ₅ CH ₂ CH ₂ CH ₂ -
21	C ₆ H ₅ C(=O)C(=O)-	4-pyrCH ₂ N-	C ₆ H ₅ CH ₂ CH ₂ CH ₂ -	C ₆ H ₅ CH ₂ CH ₂ CH ₂ -

13. A composition comprising a compound according to claim 1 and a pharmaceutically effective carrier.

14. The composition according to claim 13, further comprising a neurotrophic factor.

15. The composition according to claim 14, wherein said neurotrophic factor is selected from nerve growth factor (NGF), insulin-like growth factor (IGF-1) and its active truncated derivatives such as gIGF-1 and Des(1-3)IGF-I, acidic and basic fibroblast growth factor (aFGF and bFGF, respectively), platelet-derived growth factors (PDGF), brain-derived neurotrophic factor (BDNF), ciliary neurotrophic factors (CNTF), glial cell

-41-

line-derived neurotrophic factor (GDNF),
neurotrophin-3 (NT-3) and neurotrophin 4/5 (NT-4/5).

16. The composition according to claim 15, wherein said neurotrophic factor is nerve growth factor (NGF).

17. A method for stimulating neuronal regeneration or preventing neuronal damage or neurodegeneration in a patient or in an ex vivo nerve cell, comprising the step of administering to said patient or said nerve cell a compound according to any one of claims 1-12.

18. The method according to claim 17, wherein said compound is administered to a patient and is formulated together with a pharmaceutically suitable carrier into a pharmaceutically acceptable composition.

19. The method according to claim 18, comprising the additional step of administering to said patient a neurotrophic factor either as part of a multiple dosage form together with said compound or as a separate dosage form.

20. The method according to claim 19, wherein said neurotrophic factor is selected from nerve growth factor (NGF), insulin-like growth factor (IGF-1) and its active truncated derivatives such as gIGF-1 and Des(1-3)IGF-I, acidic and basic fibroblast growth factor (aFGF and bFGF,

-42-

respectively), platelet-derived growth factors (PDGF), brain-derived neurotrophic factor (BDNF), ciliary neurotrophic factors (CNTF), glial cell line-derived neurotrophic factor (GDNF), neurotrophin-3 (NT-3) and neurotrophin 4/5 (NT-4/5).

21. The method according to claim 20, wherein said neurotrophic factor is nerve growth factor (NGF).

22. The method according to claim 17, wherein said method is used to treat a patient suffering from a disease selected from trigeminal neuralgia, glossopharyngeal neuralgia, Bell's Palsy, myasthenia gravis, muscular dystrophy, muscle injury, progressive muscular atrophy, progressive bulbar inherited muscular atrophy, herniated, ruptured, or prolapsed intervertebrae disk syndrome's, cervical spondylosis, plexus disorders, thoracic outlet destruction syndromes, peripheral neuropathies, such as those caused by lead, dapsone, ticks, or porphyria, other peripheral myelin disorders, Alzheimer's disease, Gullain-Barre syndrome, Parkinson's disease and other Parkinsonian disorders, ALS, Tourette's syndrome, multiple sclerosis, other central myelin disorders, stroke and ischemia associated with stroke, neural paropathy, other neural degenerative diseases, motor neuron diseases, sciatic crush, neuropathy associated with diabetes, spinal cord injuries, facial nerve crush and other trauma, chemotherapy-

-43-

and other medication-induced neuropathies, and Huntington's disease.

23. The method according to claim 16, wherein said method is used to stimulate neuronal regeneration in an ex vivo nerve cell.

24. The method according to claim 23, comprising the additional step of contacting said ex vivo nerve cell with a neurotrophic factor.

25. The method according to claim 24, wherein said neurotrophic factor is selected from nerve growth factor (NGF), insulin-like growth factor (IGF-1) and its active truncated derivatives such as gIGF-1 and Des(1-3)IGF-I, acidic and basic fibroblast growth factor (aFGF and bFGF, respectively), platelet-derived growth factors (PDGF), brain-derived neurotrophic factor (BDNF), ciliary neurotrophic factors (CNTF), glial cell line-derived neurotrophic factor (GDNF), neurotrophin-3 (NT-3) and neurotrophin 4/5 (NT-4/5).

26. The method according to claim 25, wherein said neurotrophic factor is nerve growth factor (NGF).

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/18578

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D213/40 A61K31/4427 A61K31/4409 A61P25/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

CHEM ABS Data, EPO-Internal, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 96 41609 A (VERTEX PHARMA) 27 December 1996 (1996-12-27) cited in the application claims 1,12-25; examples; tables 1,2 ---	1,13, 17-26
A	WO 99 10340 A (VERTEX PHARMA) 4 March 1999 (1999-03-04) claims 1,25,30; examples --- -/--	1,13, 17-26

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

Z document member of the same patent family

Date of the actual completion of the international search

20 November 2000

Date of mailing of the international search report

08/12/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Bosma, P

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 00/18578

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>HAMILTON G S ET AL: "FKBP12-binding domain analogues of FK506 are potent, nonimmunosuppressive neurotrophic agents in vitro and promote recovery in a mouse model of Parkinson's disease"</p> <p>BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,GB,OXFORD, vol. 7, no. 13, 8 July 1997 (1997-07-08), pages 1785-1790, XP004136300</p> <p>ISSN: 0960-894X</p> <p>cited in the application</p> <p>the whole document -----</p>	<p>1,13, 17-26</p>

INTERNATIONAL SEARCH REPORT

International Application No. PCT/US 00 18578

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Present claims 1-11, 13-26 relate to an extremely large number of possible compounds. Support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT is to be found, however, for only a very small proportion of the compounds claimed. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Consequently, the search has been carried out for those parts of the claims which appear to be supported and disclosed, namely those parts relating to the compounds according to formula (I) of claim 1, in which A and B are as defined in claim 2, X is nitrogen with y is 1; and to claim 12. It is noted that the search included both the carbocyclic and heterocyclic derivatives of the moiety Q although in claim 1 only the heterocyclic derivatives have been defined, and claim 12 only covers carbocyclic rings of Q.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

Intern 1st Application No

PCT/US 00/18578

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9641609 A	27-12-1996	US 5654332 A	05-08-1997
		AU 6111996 A	09-01-1997
		BR 9609333 A	13-10-1999
		CA 2222430 A	27-12-1996
		CN 1202104 A	16-12-1998
		EP 0831812 A	01-04-1998
		PL 328723 A	15-02-1999
		US 6037370 A	14-03-2000
		US 6124328 A	26-09-2000
		ZA 9604852 A	29-07-1996
WO 9910340 A	04-03-1999	AU 8923698 A	16-03-1999
		BR 9811923 A	15-08-2000
		CN 1271354 T	25-10-2000
		EP 1007521 A	14-06-2000
		NO 20000953 A	02-05-2000
		ZA 9807478 A	22-02-1999